Lv53
850 积分 2023-10-16 加入
Independent drug action and its statistical implications for development of combination therapies
1天前
已完结
The Estimand Framework and Causal Inference: Complementary Not Competing Paradigms
21天前
已完结
A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications
24天前
已完结
Evaluating bias in the anchor method for the minimal clinically important difference: a simulation approach
26天前
已完结
Adagrasib versus docetaxel in KRAS
28天前
已完结
Adagrasib versus docetaxel in KRAS
28天前
已完结
Application of Group Sequential Methods to the 2-in-1 Design and Its Extensions for Interim Monitoring
29天前
已完结
Comparative review of novel model‐assisted designs for phase I/II clinical trials
29天前
已完结
Drift Parameter Based Sample Size Determination in Multi‐Stage Bayesian Randomized Clinical Trials
30天前
已完结
An extension to a 2-in-1 adaptive design with biomarker subpopulation selection
1个月前
已完结
皖公网安备34019202002308
